RecruitingPhase 1 / Phase 2NCT06930651
Rare condition
Camurati-Engelmann disease
11
studies recruiting now
as of 7 Sept 2026
91
studies registered in total
as of 7 Sept 2026
26
countries with a recruiting site
as of 7 Sept 2026
17 Feb 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT02504853
Natural History and Genetics of Food Allergy and Related Conditions
RecruitingPhase 1NCT05976555
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
RecruitingPhase 1 / Phase 2NCT07411599
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
RecruitingPhase 2 / Phase 3NCT06788990
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 11 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Camurati-Engelmann disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Camurati-Engelmann disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (TGFB1).
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).